Cabot Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$486K Sell
930
-969
-51% -$496K 0.05% 121
2026
Q2
$943K Buy
1,899
+969
+104% +$429K 0.1% 94
2026
Q1
$415K Hold
930
– – 0.05% 106
2025
Q4
$422K Sell
930
-645
-41% -$278K 0.05% 108
2025
Q3
$617K Buy
+1,575
New +$658K 0.07% 105

Other funds holding VRTX

Cabot Wealth Management's VRTX Position: Q3 2026 in Review

Cabot Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q3 2026, selling an estimated $496K and leaving 930 shares worth $486K. The position accounts for 0.05% of the portfolio, ranked #121.

Cabot Wealth Management first reported a position in VRTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $943K in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Cabot Wealth Management held 930 shares of Vertex Pharmaceuticals worth $486K as of Q3 2026.
  • Cabot Wealth Management sold 969 Vertex Pharmaceuticals shares in Q3 2026, an estimated $496K.
  • Vertex Pharmaceuticals made up 0.05% of Cabot Wealth Management's portfolio in Q3 2026, its #121 holding.
  • Cabot Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Cabot Wealth Management's Vertex Pharmaceuticals position peaked at $943K in Q2 2026.
  • 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Cabot Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.